NCT03101527

Brief Summary

The purpose of this study is to determine if omega-3 polyunsaturated fatty acids as a monotherapy have antidepressant effects during pregnancy. It will also provide pilot data pertaining to relationships between apparent response to omega-3 monotherapy and both plasma cytokine and erythrocyte essential fatty acid concentrations.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for early_phase_1

Timeline
Completed

Started May 2011

Shorter than P25 for early_phase_1

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2011

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2012

Completed
5.2 years until next milestone

First Submitted

Initial submission to the registry

March 30, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 5, 2017

Completed
Last Updated

April 28, 2017

Status Verified

April 1, 2017

Enrollment Period

9 months

First QC Date

March 30, 2017

Last Update Submit

April 26, 2017

Conditions

Keywords

Major Depressive Disorderomega-3 polyunsaturated fatty acidPUFAPregnancyeicosapentaenoic acid (EPA) supplementation

Outcome Measures

Primary Outcomes (4)

  • The Hamilton Rating Scale for Depression (HAM-D)

    The HAM-D is a multiple item semi-structured clinician administered questionnaire used to assess the range, type and severity of depressive symptoms observed in patients with MDD. The HAM-D24 consists of 24 symptoms, each of which is rated from 0 to 2 or 0 to 4, where 0 is none/absent. The HAMD-24 total score is calculated as the sum of the 24 individual symptom scores; the total score can range from 0 to 76. Higher HAMD-24 scores indicate more severe depression.

    Subjects were administered the HAM-D at Day 1 and every month thereafter until week 38 of their pregnancies.

  • Montgomery-Asberg Depression Scale (MADRS)

    The MADRS is a clinician administered semi-structured scaled designed to detect changes in depressive symptoms. The scale contains 10 items and ratings are graded from 0 to 6 , with 0 representing an absence of a symptom and 6 corresponding to the most severe degree of MDD symptomology.

    Subjects were administered the MADRS on Day 1 and every month thereafter until week 38 of their pregnancies.

  • Edinburgh Postnatal Depression Scale (EPDS)

    The EPDS is a self-administered depression screen for postpartum women. The EPDS consists of 10 questions. Responses are scored 0,, 1, 2, or 3 according to increased severity of the symptom. Items marked with an \* are reversed scored. A total score of 13 or more suggests follow-up intervention is warranted.

    Subjects were asked to complete the EPDS on Day 1 and every month thereafter until week 38 of their pregnancies

  • Beck Depression Scale (BDI)

    The BDI is a self-administered questionnaire developed to detect, assess, and monitor changes in depressive symptoms. It is composed of 21 items, each with 4 possible responses scored from 0 to 3 with 3 indicating a higher level of severity. For people who have been clinically diagnosed, scores from 0 to 9 represent minimal depressive symptoms, scores of 10 to 16 indicate mild depression, scores of 17 to 29 indicate moderate depression, and scores of 30 to 63 indicate severe depression.

    Subjects were asked to complete the BDI on Day 1 and every month thereafter through week 38 of their pregnancies

Study Arms (1)

Supplementation

EXPERIMENTAL

Subjects received Omega-3 PUFA supplementation

Drug: Omega-3 PUFA supplementation

Interventions

Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study

Also known as: eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA)
Supplementation

Eligibility Criteria

Age18 Years - 50 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsThis study is focused on pregnant women.
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Women with uncomplicated pregnancy within the 1st or 2nd trimester of pregnancy
  • Score of 10 or greater on the nine item Patient Health Questionnaire (PHQ-9) for depression

You may not qualify if:

  • antidepressant use in preceding month
  • use in previous 4 weeks of psychotropic medications other than hypnotics or benzodiazepines in diazepam dose-equivalents greater than or equal to 2mg/day for insomnia
  • Fish allergy
  • initiation of regularly scheduled course of psychotherapy within previous 2 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: a cross-national, ecological analysis. J Affect Disord. 2002 May;69(1-3):15-29. doi: 10.1016/s0165-0327(01)00374-3.

    PMID: 12103448BACKGROUND
  • De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci. 2003 Nov 7;73(25):3181-7. doi: 10.1016/j.lfs.2003.02.001.

    PMID: 14561523BACKGROUND
  • Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry. 1998 Mar 1;43(5):315-9. doi: 10.1016/s0006-3223(97)00206-0.

    PMID: 9513745BACKGROUND
  • Rees AM, Austin MP, Owen C, Parker G. Omega-3 deficiency associated with perinatal depression: case control study. Psychiatry Res. 2009 Apr 30;166(2-3):254-9. doi: 10.1016/j.psychres.2007.12.011. Epub 2009 Mar 5.

    PMID: 19268372BACKGROUND

MeSH Terms

Conditions

Depressive Disorder, Major

Interventions

Eicosapentaenoic AcidDocosahexaenoic Acids

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Fatty Acids, Omega-3Dietary Fats, UnsaturatedDietary FatsFatsLipidsEicosanoidsFatty Acids, UnsaturatedFatty AcidsFish OilsOils

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: A single group model was used: pregnant women.
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 30, 2017

First Posted

April 5, 2017

Study Start

May 1, 2011

Primary Completion

February 1, 2012

Study Completion

February 1, 2012

Last Updated

April 28, 2017

Record last verified: 2017-04

Data Sharing

IPD Sharing
Will not share

The Investigator does not intend to share IPD